Clinical Trials Browser

Has results × Carcinoma, Squamous Cell × Nivolumab × Clear all

NCT03341936 2025-06-18

Neodjuvant Nivolumab and Lirilumab, Followed by Surgery, Followed by Adjuvant Nivolumab and Lirilumab, in SCCHN

Phase 2 Active not recruiting

29 enrolled 11 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell

NCT03944915 2025-05-11

DEPEND

Phase 2 Completed

35 enrolled 14 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell

NCT03190174 2025-02-17

Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers

Phase 1/2 Completed

34 enrolled 14 charts

DermatologicGastrointestinalGenitourinarySarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Chordoma, Carcinoma, Hepatocellular, Melanoma, Sarcoma, Sarcoma, Ewing, Colorectal Neoplasms, Desmoid Tumors, Perivascular Epithelioid Cell Neoplasms

NCT03715946 2025-01-13

Adjuvant De-Escalated Radiation + Adjuvant Nivolumab for Intermediate-High Risk P16+ Oropharynx Cancer

Phase 2 Completed

40 enrolled 69 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms, Oropharyngeal Neoplasms

NCT03215810 2023-07-24

Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer

Phase 1 Completed

20 enrolled 10 charts

Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Recurrence, Carcinoma, Adenosquamous